Clinical Solutions

Transforming Clinical Trial Oversight: Enabling Enterprise-wide RBQM Adoption through Centralized Monitoring and Strategic Advisory

Q: What is Risk-Based Quality Management (RBQM) in clinical trials?

Risk-Based Quality Management (RBQM) is a proactive approach to clinical trial oversight that focuses resources on identifying, assessing, and mitigating the most critical risks to patient safety and data integrity. Guided by ICH E6(R2) guidelines and FDA expectations, RBQM replaces traditional, resource-intensive monitoring models with data-driven, risk-focused strategies that enable sponsors to detect and respond to issues earlier and more efficiently.

Q: What is centralized monitoring in clinical trials?

Centralized monitoring is a remote, data-driven approach to clinical trial oversight in which a dedicated team continuously reviews data from all active study sites to detect risk signals, identify cross-site patterns, and flag emerging issues before they escalate. It complements or reduces the need for frequent on-site monitoring visits, enabling faster and more consistent risk detection across the clinical portfolio.

Q: What is the difference between RBQM and traditional monitoring?

Traditional monitoring relies heavily on on-site visits and manual data review, making it resource-intensive and often retrospective. RBQM uses centralized statistical monitoring, key risk indicators (KRIs), and quality tolerance limits (QTLs) to proactively identify risks in real time across sites and studies, enabling targeted interventions instead of routine, blanket oversight.

Q: Why is RBQM important for pharmaceutical sponsors?

RBQM is important because it aligns with evolving regulatory expectations under ICH E6(R2) and FDA guidance, reduces the cost and operational burden of traditional monitoring, and improves the quality and speed of risk detection. For sponsors managing large clinical portfolios, RBQM enables consistent, enterprise-wide visibility into trial risk that cannot be achieved through conventional monitoring alone.

Q: What are the biggest challenges in implementing RBQM?

The most common challenges include fragmented risk management infrastructure without enterprise standards, limited internal expertise in centralized statistical monitoring and risk interpretation, and technology adoption that outpaces process redesign. Teams may have dashboards but lack clear guidance on how to act on insights. Successful RBQM implementation requires strategic alignment, standardized processes, and investment in building internal capability alongside technology deployment.

Download Case Study

How a global pharmaceutical sponsor went from fragmented, reactive risk management to an enterprise-wide RBQM capability and what it took to get there.

The Challenge - A gap between regulatory intent and operational reality

Risk libraries, quality tolerance limits, and monitoring workflows existed in silos across therapeutic areas, with no enterprise standard governing how they were applied. Technology adoption had outpaced process redesign, leaving teams with dashboards they did not know how to act on. Internal expertise in centralized statistical monitoring and risk-based decision-making was limited, creating reliance on external vendors for even routine risk assessments.

The Approach - Strategic advisory paired with hands-on execution

Axtria partnered with the client across three phases: first designing a unified RBQM framework and consolidated risk libraries; then assuming responsibility for continuous centralized monitoring across the entire active portfolio; and finally building internal capability through a customized training and enablement program. All three workstreams ran within a single engagement, functioning as a true extension of the client's clinical operations.

The Outcome - A proactive, self-sustaining RBQM function

The client moved from fragmented, reactive risk oversight to a cohesive, proactive quality management function with portfolio-wide visibility. Risk detection and response times improved significantly, and internal teams developed fluency to own RBQM execution with progressively less external support thus reducing long-term operational dependency while maintaining consistent standards across the portfolio.

Key Takeaways from the Engagement

How to structure a phased RBQM rollout that connects strategy design to live monitoring without disrupting ongoing trials.
What it takes to build QTL frameworks that work across therapeutic areas and produce actionable escalation pathways, not just dashboards.
Why capability transfer must be intentional and how to design an enablement program that reduces vendor dependency over time.
How centralized monitoring accelerates risk response by shifting teams from retrospective review to proactive, signal-driven intervention.

Successful RBQM implementation requires more than technology, it demands strategic alignment, operational discipline, and investment in people. By partnering with Axtria for both guidance and execution, the client transformed a fragmented, reactive approach to clinical trial risk into a cohesive, proactive quality management function.